|
1
|
Maruthappu M, Watkins J, Noor AM, Williams
C, Ali R, Sullivan R, Zeltner T and Atun R: Economic downturns,
universal health coverage, and cancer mortality in high-income and
middle-income countries, 1990–2010: A longitudinal analysis.
Lancet. 388:684–695. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosell R, Bivona TG and Karachaliou N:
Genetics and biomarkers in personalisation of lung cancer
treatment. Lancet. 382:720–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsao MS, Sakurada A, Cutz JC, Zhu CQ,
Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, et
al: Erlotinib in lung cancer-molecular and clinical predictors of
outcome. N Engl J Med. 353:133–144. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lastwika KJ, Wilson W III, Li QK, Norris
J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, et
al: Control of PD-L1 expression by oncogenic activation of the
AKT-mTOR pathway in non-small cell lung cancer. Cancer Res.
76:227–238. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Facchinetti F, Marabelle A, Rossi G, Soria
JC, Besse B and Tiseo M: Moving immune checkpoint blockade in
thoracic tumors beyond NSCLC. J Thorac Oncol. 11:1819–1836. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: Introduction to the 2015 world health
organization classification of tumors of the lung, pleura, thymus,
and heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsao AS, Scagliotti GV, Bunn PA Jr,
Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU,
McWilliams A, Tsao MS, et al: Scientific advances in lung cancer
2015. J Thorac Oncol. 11:613–638. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dirks RA, Stunnenberg HG and Marks H:
Genome-wide epigenomic profiling for biomarker discovery. Clin
Epigenetics. 8:1222016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Johnson EM, Kinoshita Y and Daniel DC: A
new member of the MCM protein family encoded by the human MCM8
gene, located contrapodal to GCD10 at chromosome band 20p12.3–13.
Nucleic Acids Res. 31:2915–2925. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bik KT: MCM proteins in DNA replication.
Annu Rev Biochem. 68:649–686. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Remus D, Beuron F, Tolun G, Griffith JD,
Morris EP and Diffley JF: Concerted loading of Mcm2-7 double
hexamers around DNA during DNA replication origin licensing. Cell.
139:719–730. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maiorano D, Cuvier O, Danis E and Méchali
M: MCM8 is an MCM2-7-related protein that functions as a DNA
helicase during replication elongation and not initiation. Cell.
120:315–328. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lõoke M, Maloney MF and Bell SP: Mcm10
regulates DNA replication elongation by stimulating the CMG
replicative helicase. Genes Dev. 31:291–305. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hua C, Zhao G, Li Y and Bie L:
Minichromosome maintenance (MCM) family as potential diagnostic and
prognostic tumor markers for human gliomas. BMC Cancer. 14:5262014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peng YP, Zhu Y, Yin LD, Zhang JJ, Guo S,
Fu Y, Miao Y and Wei JS: The expressionand prognostic roles of MCMs
in pancreatic cancer. PLoS One. 11:e01641502016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kwok HF, Zhang SD, McCrudden CM, Yuen HF,
Ting KP, Wen Q, Khoo US and Chan KY: Prognostic signifcance of
minichromosome maintenance proteins in breast cancer. Am J Cancer
Res. 5:52–71. 2014.PubMed/NCBI
|
|
21
|
Liao X, Liu X, Yang C, Wang X, Yu T, Han
C, Huang K, Zhu G, Su H, Qin W, et al: Distinct diagnostic and
prognostic values of minichromosome maintenance gene expression in
patients with hepatocellular carcinoma. J Cancer. 9:2357–2373.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Werynska B, Pula B, Muszczynska-Bernhard
B, Piotrowska A, Jethon A, Podhorska-Okolow M, Dziegiel P and
Jankowska R: Correlation between expression of metallothionein and
expression of Ki-67 and MCM-2 proliferation markers in non-small
cell lung cancer. Anticancer Res. 31:2833–2839. 2011.PubMed/NCBI
|
|
23
|
Wu W, Wang X, Shan C, Li Y and Li F:
Minichromosome maintenance protein 2 correlates with the malignant
status and regulates proliferation and cell cycle in lung squamous
cell carcinoma. Onco Targets Ther. 11:5025–5034. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fujioka S, Shomori K, Nishihara K, Yamaga
K, Nosaka K, Araki K, Haruki T, Taniguchi Y, Nakamura H and Ito H:
Expression of minichromosome maintenance 7 (MCM7) in small lung
adenocarcinomas (pT1): Prognostic implication. Lung Cancer.
65:223–229. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45((W1)):
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chansky K, Detterbeck FC, Nicholson AG,
Rusch VW, Vallières E, Groome P, Kennedy C, Krasnik M, Peake M,
Shemanski L, et al: The IASLC lung cancer staging project: External
validation of the revision of the TNM stage groupings in the eighth
edition of the TNM classification of lung cancer. J Thorac Oncol.
12:1109–1121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pontén F, Jirström K and Uhlen M: The
human protein atlas-a tool for pathology. J Pathol. 216:387–393.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li Q, Birkbak NJ, Gyorffy B, Szallasi Z
and Eklund AC: Jetset: Selecting the optimal microarray probe set
to represent a gene. BMC Bioinformatics. 12:4742011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yuan H, Yan M, Zhang G, Liu W, Deng C,
Liao G, Xu L, Luo T, Yan H, Long Z, et al: CancerSEA: A cancer
single-cell state atlas. Nucleic Acids Res. 47(D1): D900–D908.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hou J, Aerts J, den Hamer B, van Ijcken W,
den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens J
Hoogsteden HC, et al: Gene expression-based classification of
non-small cell lung carcinomas and survival prediction. PLoS One.
5:e103122010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Selamat SA, Chung BS, Girard L, Zhang W,
Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL, et al:
Genome-scale analysis of DNA methylation in lung adenocarcinoma and
integration with mRNA expression. Genome Res. 22:1197–1211. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ,
Liang SC, Lin CH, Whang-Peng J, Hsu SL, Chen CH and Huang CY:
Selection of DDX5 as a novel internal control for Q-RT-PCR from
microarray data using a block bootstrap re-sampling scheme. BMC
Genomics. 8:1402017. View Article : Google Scholar
|
|
36
|
Okayama H, Kohno T, Ishii Y, Shimada Y,
Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S,
et al: Identification of genes upregulated in ALK-positive and
EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res.
72:100–111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Landi MT, Dracheva T, Rotunno M, Figueroa
JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et
al: Gene expression signature of cigarette smoking and its role in
lung adenocarcinoma development and survival. PLoS One.
3:e16512008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Stearman RS, Dwyer-Nield L, Zerbe L,
Blaine SA, Chan Z, Bunn PA Jr, Johnson GL, Hirsch FR, Merrick DT,
Franklin WA, et al: Analysis of orthologous gene expression between
human pulmonary adenocarcinoma and a carcinogen-induced murine
model. Am J Pathol. 167:1763–1775. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Beer DG, Kardia SL, Huang CC, Giordano TJ,
Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al:
Gene-expression profiles predict survival of patients with lung
adenocarcinoma. Nat Med. 8:816–824. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Garber ME, Troyanskaya OG, Schluens K,
Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen
GD, Perou CM, Whyte RI, et al: Diversity of gene expression in
adenocarcinoma of the lung. Proc Natl Acad Sci USA. 98:13784–13789.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim KT, Lee HW, Lee HO, Kim SC, Seo YJ,
Chung W, Eum HH, Nam DH, Kim J, Joo KM and Park WY: Single-cell
mRNA sequencing identifies subclonal heterogeneity in anti-cancer
drug responses of lung adenocarcinoma cells. Genome Biol.
16:1272015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Simon NE and Schwacha A: The Mcm2-7
replicative helicase: A promising chemotherapeutic target. Biomed
Res Int. 2014:5497192014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu YZ, Wang BS, Jiang YY, Cao J, Hao JJ,
Zhang Y, Xu X, Cai Y and Wang MR: MCMs expression in lung cancer:
Implication of prognostic significance. J Cancer. 8:3641–3647.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tachibana KE, Gonzalez MA and Coleman N:
Cell-cycle-dependent regulation of DNA replication and its
relevance to cancer pathology. J Pathol. 205:123–129. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cheung CHY, Hsu CL, Chen KP, Chong ST1, Wu
CH, Huang HC and Juan HF: MCM2-regulated functional networks in
lung cancer by multi-dimensional proteomic approach. Sci Rep.
7:133022017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang X, Teng Y, Yang F, Wang M, Hong X,
Ye LG, Gao YN and Chen GY: MCM2 is a therapeutic target of
lovastatin in human non-small cell lung carcinomas. Oncol Rep.
33:2599–2605. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Veena VS, Rajan K, Saritha VN, Preethi
Sara G, Chandramohan K, Jayasree K, Thara S and Sujathan K: DNA
replication licensing proteins for early detection of lung cancer.
Asian Pac J Cancer Prev. 18:3041–3047. 2017.PubMed/NCBI
|
|
48
|
Yang J, Ramnath N, Moysich KB, Asch HL,
Swede H, Alrawi SJ, Huberman J, Geradts J, Brooks JS and Tan D:
Prognostic significance of MCM2, Ki-67 and gelsolin in non-small
cell lung cancer. BMC Cancer. 6:2032006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kadara H, Lacroix L, Behrens C, Solis L,
Gu X, Lee JJ, Tahara E, Lotan D, Hong WK, Wistuba II and Lotan R:
Identification of gene signatures and molecular markers for human
lung cancer prognosis using an in vitro lung carcinogenesis system.
Cancer Prev Res (Phila). 2:702–711. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ramnath N, Hernandez FJ, Tan DF, Huberman
JA, Natarajan N, Beck AF, Hyland A, Todorov IT, Brooks JS and
Bepler G: MCM2 is an independent predictor of survival in patients
with non-small-cell lung cancer. J Clin Oncol. 19:4259–4266. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ha SA, Shin SM, Namkoong H, Lee H, Cho GW,
Hur SY, Kim TE and Kim JW: Cancer-associated expression of
minichromosome maintenance 3 gene in several human cancers and its
involvement in tumorigenesis. Clin Cancer Res. 10:8386–8395. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xu H, Ma J, Wu J, Chen L, Sun F, Qu C,
Zheng D and Xu S: Gene expression profiling analysis of lung
adenocarcinoma. Braz J Med Biol Res. 49(pii):
S0100–879X2016000300601. 2016.
|
|
53
|
Zhang C, Elkahloun AG, Liao H, Delaney S,
Saber B, Morrow B, Prendergast GC, Hollander MC, Gills JJ and
Dennis PA: Expression signatures of the lipid-based Akt inhibitors
phosphatidylinositol ether lipid analogues in NSCLC cells. Mol
Cancer Ther. 10:1137–1148. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yi J, Wei X, Li X, Wan L, Dong J and Wang
R: A genome-wide comprehensive analysis of alterations in driver
genes in non-small-cell lung cancer. Anticancer Drugs. 29:10–18.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi
E, Takeda K, Aburatani H, Oizumi S, Konishi J, Kaga K, Matsuno Y,
et al: Minichromosome maintenance (MCM) protein 4 as a marker for
proliferation and its clinical and clinicopathological significance
in non-small cell lung cancer. Lung Cancer. 72:229–237. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Vigouroux C, Casse JM, Battaglia-Hsu SF,
Brochin L, Luc A, Paris C, Lacomme S, Gueant JL, Vignaud JM and
Gauchotte G: Methyl(R217)HuR and MCM6 are inversely correlated and
are prognostic markers in non small cell lung carcinoma. Lung
Cancer. 89:189–196. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Fei L, Ma Y, Zhang M, Liu X, Luo Y, Wang
C, Zhang H, Zhang W and Han Y: RACK1 promotes lung cancer cell
growth via an MCM7/RACK1/Akt signaling complex. Oncotarget.
8:40501–40513. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lo Sardo F, Forcato M, Sacconi A, Capaci
V, Zanconato F, Di Agostino S, Del Sal G, Pandolfi PP, Strano S,
Bicciato S and Blandino G: MCM7 and its hosted miR-25, 93 and 106b
cluster elicit YAP/TAZ oncogenic activity in lung cancer.
Carcinogenesis. 38:64–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Toyokawa G, Masuda K, Daigo Y, Cho HS,
Yoshimatsu M, Takawa M, Hayami S, Maejima K, Chino M, Field HI, et
al: Minichromosome Maintenance protein 7 is a potential therapeutic
target in human cancer and a novel prognostic marker of non-small
cell lung cancer. Mol Cancer. 10:652011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Liu YZ, Jiang YY, Hao JJ, Lu SS, Zhang TT,
Shang L, Cao J, Song X, Wang BS, Cai Y, et al: Prognostic
significance of MCM7 expression in the bronchial brushings of
patients with non-small cell lung cancer (NSCLC). Lung Cancer.
77:176–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cui F, Hu J, Ning S, Tan J and Tang H:
Overexpression of MCM10 promotes cell proliferation and predicts
poor prognosis in prostate cancer. Prostate. 78:1299–1310. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Brown DC and Gatter KC: Ki67 protein: The
immaculate deception? Histopathology. 40:2–11. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Aporowicz M, Czopnik P, Kubicka E,
Piotrowska A, Dziegiel P, Bolanowski M and Domoslawski P:
Minichromosome maintenance proteins MCM-3, MCM-5, MCM-7, and Ki-67
as proliferative markers in adrenocortical tumors. Anticancer Res.
39:1151–1159. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Choy B, LaLonde A, Que J, Wu T and Zhou Z:
MCM4 and MCM7, potential novel proliferation markers, significantly
correlated with Ki-67, Bmi1, and cyclin E expression in esophageal
adenocarcinoma, squamous cell carcinoma, and precancerous lesions.
Hum Pathol. 57:126–135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Giaginis C, Giagini A, Tsourouflis G,
Gatzidou E, Agapitos E, Kouraklis G and Theocharis S: MCM-2 and
MCM-5 expression in gastric adenocarcinoma: Clinical significance
and comparison with Ki-67 proliferative marker. Dig Dis Sci.
56:777–785. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Schrader C, Janssen D, Klapper W, Siebmann
JU, Meusers P, Brittinger G, Kneba M, Tiemann M and Parwaresch R:
Minichromosome maintenance protein 6, a proliferation marker
superior to Ki-67 and independent predictor of survival in patients
with mantle cell lymphoma. Br J Cancer. 93:939–945. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lampert IA, Horncastle D, Dilworth S,
Roberts I, Alison MR and Naresh KN: The expression of
minichromosome maintenance protein-2 in normal and abnormal
megakaryocytes and comparison with the proliferative marker Ki-67.
Br J Haematol. 131:490–494. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Endl E, Kausch I, Baack M, Knippers R,
Gerdes J and Scholzen T: The expression of Ki-67, MCM3, and p27
defines distinct subsets of proliferating, resting, and
differentiated cells. J Pathol. 195:457–462. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Chatrath P, Scott IS, Morris LS, Davies
RJ, Rushbrook SM, Bird K, Vowler SL, Grant JW, Saeed IT, Howard D,
et al: Aberrant expression of minichromosome maintenance protein-2
and Ki67 in laryngeal squamous epithelial lesions. Br J Cancer.
89:1048–1054. 2003. View Article : Google Scholar : PubMed/NCBI
|
